References of "Beckers, Albert"
     in
Bookmark and Share    
See detailMultiple Endocrine Neoplasia 1 : From the clinic to the gene
Beckers, Albert ULg

Scientific conference (1998, January 30)

Detailed reference viewed: 5 (0 ULg)
See detailMutation analysis of the MEN1 gene in Belgian patients with multiple endocrine neoplasia type I and related diseases
Poncin, Jacques ULg; Abs, R.; Velkeniers, B. et al

in IV european Congress of Endocrinology - Abstract book (1998)

Detailed reference viewed: 4 (0 ULg)
See detailOverview of presurgical somatostatin analog treatment in acromegaly
Beckers, Albert ULg; Stevenaert, Achille ULg

in IV european Congress of Endocrinology - Abstract book (1998)

Detailed reference viewed: 6 (0 ULg)
See detailMutation analysis of the MEN1 gene in Belgian patients with multiple endocrine neoplasia type I and related diseases
Poncin, Jacques ULg; Abs, R.; Velkeniers, B. et al

in 5th Euroregional Oncology meeting - abstract book (1998)

Detailed reference viewed: 6 (0 ULg)
See detailThe spectrum of MEN1 gene mutations in Belgian patients with MEN1 and related diseases
Poncin, Jacques ULg; Abs, R.; Velkeniers, B. et al

in The 5th International Pituitary congress - Abstract book (1998)

Detailed reference viewed: 5 (0 ULg)
See detailInsuffisance hypophysaire et amaurose subaiguës causées par une pseudotumeur inflammatoire extensive du sinus sphénoïde
Hansen, Isabelle ULg; Petrossians, Patrick ULg; Flandroy, Pierre et al

in XVI Congrès de la Société Française d'Endocrinologie - Abstract book (1998)

Detailed reference viewed: 48 (0 ULg)
See detailPresurgical octreotide treatment in acromegaly
Stevenaert, Achille ULg; Beckers, Albert ULg

in 5th International Pituitary congress - abstract book (1998)

Detailed reference viewed: 6 (0 ULg)
See detailThe spectrum of MEN1 gene mutations in Belgian patients with MEN1 and related diseases
Poncin, Jacques ULg; Abs, R.; Velkeniers, B. et al

in 80th Annual Meeting of the Endocrine society - Abstract book (1998)

Detailed reference viewed: 5 (0 ULg)
Full Text
Peer Reviewed
See detailMutation analysis of the MEN1 gene in multiple endocrine neoplasia type 1, familial acromegaly and familial isolated hyperparathyroidism.
Teh, B. T.; Kytola, S.; Farnebo, F. et al

in Journal of Clinical Endocrinology and Metabolism (1998), 83(8), 2621-2626

Multiple endocrine neoplasia type 1 (MEN 1) is an autosomal dominant disease characterized by neoplasia of the parathyroid glands, the endocrine pancreas, and the anterior pituitary gland. In addition ... [more ▼]

Multiple endocrine neoplasia type 1 (MEN 1) is an autosomal dominant disease characterized by neoplasia of the parathyroid glands, the endocrine pancreas, and the anterior pituitary gland. In addition, families with isolated endocrine neoplasia, notably familial isolated hyperparathyroidism (FIHP) and familial acromegaly, have also been reported. However, whether these families constitute MEN 1 variants or separate entities remains speculative as the genetic bases for these diseases are unclear. The gene for MEN 1 has recently been cloned and characterized. Using single strand conformation analysis (SSCA) and sequencing, we performed mutation analysis in: a) a total of 55 MEN 1 families from 7 countries, b) 13 isolated MEN 1 cases without family history of the disease, c) 8 acromegaly families, and d) 4 FIHP families. Mutations were identified in 27 MEN 1 families and 9 isolated cases. The 22 different mutations spread across most of the 9 translated exons and included frameshift (11), nonsense (6), splice (2), missense mutations (2), and in-frame deletions (1). Among the 19 Finnish MEN 1 probands, a 1466del12 mutation was identified in 6 families with identical 11q13 haplotypes and in 2 isolated cases indicating a common founder. One frameshift mutation caused by 359del4 (GTCT) was found in 1 isolated case and 4 kindreds of different origin and haplotypes; this mutation therefore represents a common "warm" spot in the MEN1 gene. By analyzing the DNA of the parents of an isolated case one mutation was confirmed to be de novo. No mutation was found in any of the acromegaly and small FIHP families, suggesting that genetic defects other than the MEN1 gene might be involved and that additional such families need to be analyzed. [less ▲]

Detailed reference viewed: 81 (5 ULg)
Peer Reviewed
See detailAspects genetiques du male 46, XX.
Marquet, F.; Beckers, Albert ULg; Verloes, Alain ULg

in Revue Médicale de Liège (1998), 53(12), 738-740

The XX males represent a proportion of 1/25 of all patients suffering of the Klinefelter syndrome. From a clinical and endocrinological point of view, they exhibit a hypogonadotropic hypogonadism ... [more ▼]

The XX males represent a proportion of 1/25 of all patients suffering of the Klinefelter syndrome. From a clinical and endocrinological point of view, they exhibit a hypogonadotropic hypogonadism. Isolated cases are rare and familial forms are exceptional. The XX males may be divided in 3 subgroups: 46, XX males with the SRY gene; 46, XX males without the SRY gene and XX/XY mosaics. [less ▲]

Detailed reference viewed: 56 (5 ULg)
Full Text
See detailLes hypertensions artérielles d'origine endocrinienne.
Beckers, Albert ULg

in Tempo Médical (1998), 196

Les hypertensions artérielles d'origine endocrinienne représentent environ 3 à 5 % des hypertensions artérielles, parmi lesquelles les formes les plus sévères. Lors du diagnostic, une importance ... [more ▼]

Les hypertensions artérielles d'origine endocrinienne représentent environ 3 à 5 % des hypertensions artérielles, parmi lesquelles les formes les plus sévères. Lors du diagnostic, une importance particulière sera accordée à une sémiologie évocatrice. Une cause endocrinienne sera également activement recherchée dans les cas de mauvaises réponses au traitement classique de l'hypertension artérielle. [less ▲]

Detailed reference viewed: 25 (0 ULg)
Peer Reviewed
See detailLe cas clinique du mois Un homme a caryotype 46,XX.
Marquet, F.; Verloes, Alain ULg; Beckers, Albert ULg

in Revue Médicale de Liège (1998), 53(9), 515-517

The XX males represent a rare expression of the Klinefelter syndrome associated with hypergonadotropic hypogonadism. Generally the patients are of small stature with normal secondary sexual male features ... [more ▼]

The XX males represent a rare expression of the Klinefelter syndrome associated with hypergonadotropic hypogonadism. Generally the patients are of small stature with normal secondary sexual male features but with small testes and constant sterility. The plasma concentrations of FSH and LH are very high in accordance with the decrease of the testicular function. From the genetic point of view, the XX males may be divided in 3 groups: 1) in 80% of cases, the XX males bear the SRY gene and exhibit a XY translation during the paternal meiosis with the presence of the SRY gene on one of the X chromosomes as a marker of the male differentiation; 2) in 10% of cases, the males are (SRY-)XX; the abnormal development is then due to other genes than the TDF, which, when mutated, can induce sexual male differentiation. The remaining 10% of cases are due to chromosomal mosaicism with more XX than XY. [less ▲]

Detailed reference viewed: 186 (4 ULg)
Peer Reviewed
See detailComment j'explore ... les pathologies thyroidiennes par cytoponction echoguidee.
Meunier, Paul ULg; Lebrun, Yves ULg; Quatresooz, Pascale ULg et al

in Revue Médicale de Liège (1998), 53(12), 784-787

From a retrospective study of 259 files, the authors stress the value of US-guided thyroid cytoponction and its essential role in case of thyroid cancer suspicion. This very specific and inexpensive ... [more ▼]

From a retrospective study of 259 files, the authors stress the value of US-guided thyroid cytoponction and its essential role in case of thyroid cancer suspicion. This very specific and inexpensive method fits perfectly into the other exploration techniques. It is the deciding factor in the thyroid nodule differential diagnostic and therapeutic planning. [less ▲]

Detailed reference viewed: 68 (5 ULg)
See detailLes mutations NEM-1 dans les familles belges
Beckers, Albert ULg

Scientific conference (1997, November)

Detailed reference viewed: 28 (7 ULg)
Full Text
Peer Reviewed
See detailL'hyperaldostéronisme primaire. Mise au point et traitement raisonnés.
Baudoin, Béatrice ULg; Hamoir, Etienne ULg; Defechereux, Thierry et al

in Revue Française d'Endocrinologie Clinique, Nutrition, et Métabolisme (La) (1997), 38(6), 555-568

Depuis la découverte par Jérôme Conn, en 1954, de l'adénome sécréteur d'aldostérone (ou aldostéronome), neuf variétés ou associations particulières d'hyperaldostéronisme primaire ont été décrites. La ... [more ▼]

Depuis la découverte par Jérôme Conn, en 1954, de l'adénome sécréteur d'aldostérone (ou aldostéronome), neuf variétés ou associations particulières d'hyperaldostéronisme primaire ont été décrites. La manifestation principale de ce désordre endocrinien est l'hypertension artérielle, réfractaire aux thérapeutiques habituelles. Cependant, certains types d'hyperaldostéronisme sont sensibles à la chirurgie qui éradique cette hypertension et ses conséquences. Il importe donc de distinguer ces différentes variétés grâce aux moyens d'investigations actuellement à notre disposition afin d'appliquer le traitement le plus judicieux dans chaque cas. [less ▲]

Detailed reference viewed: 134 (2 ULg)
See detailLes hypertensions artérielles d'origine endocrinienne
Beckers, Albert ULg

Scientific conference (1997, October 17)

Detailed reference viewed: 10 (0 ULg)
Full Text
Peer Reviewed
See detailTwo years of replacement therapy in adults with growth hormone deficiency.
Verhelst, J.; Abs, R.; Vandeweghe, M. et al

in Clinical Endocrinology (1997), 47(4), 485-494

OBJECTIVES: Although several studies have shown beneficial short-term effects of recombinant human growth hormone (rhGH) therapy in adult GH deficient (GHD) patients, few data are available on large ... [more ▼]

OBJECTIVES: Although several studies have shown beneficial short-term effects of recombinant human growth hormone (rhGH) therapy in adult GH deficient (GHD) patients, few data are available on large groups of patients treated for more than one year. In addition, the optimal dose of rhGH for each patient and the baseline parameters that predict which patients will benefit most from therapy or will have adverse events are not entirely elucidated. DESIGN: 148 adult GHD patients were enrolled in a multicentre 2-year rhGH replacement study which was placebo controlled for the first six months. rhGH (Genotropin/Genotonorm Pharmacia & Upjohn) was given in a dose of 0.25 IU/kg/week sc (1.5 IU/m2/day). MEASUREMENTS: Every 3-6 months body composition was measured using body impedance analysis and general well being was assessed using the Nottingham Health Profile (NHP) and social self-reporting questionnaire. At the same time patients had a full clinical examination and blood was sampled for glucose, HbA1c, IGF-1, creatinine, full blood count, thyroid hormones and liver function tests. RESULTS: With rhGH therapy IGF-1 levels increased from -2.00 +/- 2.60 SDS to 1.47 +/- 2.6 SDS after six months (P < 0.001), continued to rise despite no change in dose to 1.84 +/- 2.8 SDS after one year and remained constant thereafter (1.98 +/- 2.4 after 2 years). 56% of patients ultimately attained supranormal IGF-1 levels (+2 SD), 22% had levels below the mean, of which 9% were below -2 SD. Within 3 months lean body mass (LBM) increased by +5.09% (P < 0.001), total body water (TBW) by +5.40% (P < 0.001), while body fat (BF) dropped by -10.89% (P < 0.001) and waist circumference by -1.42% (P < 0.004). These effects were maintained during the first year of therapy, but the effect was attenuated after 24 months: LBM, +3.91% (P < 0.001); TBW, +3.28%, P < 0.001, BF, -6.42% (P < 0.001) and waist -2.22% (P < 0.009). Individual differences in response were large and could not be predicted by any of the baseline parameters, except for a better response in males. Treatment resulted in a large and progressive improvement on the NHP scale, especially energy, emotions and sleep, but a similar change was also found in patients during placebo treatment. With rhGH the number of full days of sick leave/6 months decreased from 12.17 +/- 3.90 days (SEM) to 7.15 +/- 3.50 days after six months (P = 0.009), 2.93 +/- 1.55 days after 12 months (P = 0.01), 0.39 +/- 0.17 days after 18 months (P < 0.001) and 3.3 +/- 2.51 days after 24 months (P = 0.026). Similarly, the hospitalization rate went down from 14.9 to 7% after 6 months and remained at this level thereafter (P = 0.12). About one third of patients on rhGH experienced fluid-related adverse events, most often within the first 3 months. They usually disappeared spontaneously or responded well to dose reduction. Cumulative dropout rates were 29% after 1 year and 38% after two years. Two thirds of these patients stopped treatment because of insufficient subjective improvement. Neither drop-outs nor fluid retention could not be predicted by any of the baseline parameters. CONCLUSIONS: We confirmed in a large group of patients the beneficial effects of rhGH therapy on body composition, metabolic parameters and general well-being and found a consistent drop in number of sick days and hospitalization rate. These effects were maintained during two years of therapy, except for an attenuation in body composition changes after 24 months. The high incidence of fluid-related adverse events suggests that it may be better to start with lower doses of rhGH and to increase the dose more slowly over a number of weeks. The finding of suboptimal high or low IGF-1 levels in many patients reinforces guidelines not to give rhGH in a weight-dependent dose but to titrate it individually for each patient. [less ▲]

Detailed reference viewed: 32 (1 ULg)
See detailTreatment options for recurrent pituitary tumours
Beckers, Albert ULg

Scientific conference (1997, September)

Detailed reference viewed: 7 (0 ULg)